Abstract The American Joint Committee on Cancer (AJCC) staging system for all cancer
sites, including gastroenteropancreatic neuroendocrine tumors (GEP‐NETs), is meant to be …

MATERIALS AND METHODS Systematic Review To inform the development of these
guidelines, a systematic review of evidence was performed. We followed the Preferred …

This article is the result of the North American Neuroendocrine Tumor Society consensus
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …

High-grade neuroendocrine neoplasms are a rare disease entity and account for
approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an …

There have been numerous advances in all aspects of the carcinoid-syndrome, which is the
most common functional syndrome neuroendocrine tumors produce. These advances are …

PURPOSE To develop recommendations for systemic therapy for well-differentiated grade 1
(G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) …

Neuroendocrine neoplasms (NENs) are derived from neuroendocrine cell system and can
have benign or malignant characteristics. They are rare tumors, but have been increasing in …

Context.—According to the 2017 World Health Organization classification, pancreatic
neuroendocrine neoplasms (PanNENs) include a new category of pancreatic …

There is no consensus on optimal follow-up for completely resected gastroenteropancreatic
neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize …

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor
radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine …